Trade Secrets Strategies in Early-Stage R&D
Intellectual Property Chair Michael Renaud, Member Vanessa Yen, Counsel Evan Diamond, and Associate Gabriella Flick co-authored an article in Bloomberg Law providing key insight into trade secret strategies in early R&D scenarios in the pharmaceutical, medical device, and high-tech industries.
The authors wrote, “As pharmaceutical, medical device and high-tech innovations involve increasingly sophisticated technologies … fewer companies can “go it alone” in researching and developing cutting-edge products. Instead, companies and research institutions frequently collaborate even in the early stages of R&D. While such collaborations can yield great rewards, there are also risks when researchers and companies share highly-sensitive proprietary information.”
Copyright 2024 Bloomberg Industry Group, Inc. (800-372-1033) Reproduced with permission.
Source